IOVA Iovance Biotherapeutics Inc

Price (delayed)

$16.79

Market cap

$4.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.89

Enterprise value

$4.58B

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy ...

Highlights
IOVA's revenue has soared by 68% QoQ
The EPS has grown by 24% YoY and by 9% from the previous quarter
IOVA's equity is up by 17% year-on-year but it is down by 13% since the previous quarter
The gross profit has plunged by 68% from the previous quarter
The company's quick ratio fell by 40% YoY and by 33% QoQ

Key stats

What are the main financial stats of IOVA
Market
Shares outstanding
279.31M
Market cap
$4.69B
Enterprise value
$4.58B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.35
Price to sales (P/S)
3,320.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,855.43
Earnings
Revenue
$1.19M
EBIT
-$447.52M
EBITDA
-$414.39M
Free cash flow
-$384.11M
Per share
EPS
-$1.89
Free cash flow per share
-$1.63
Book value per share
$2.28
Revenue per share
$0.01
TBVPS
$2.34
Balance sheet
Total assets
$780.35M
Total liabilities
$195.74M
Debt
$75.86M
Equity
$584.61M
Working capital
$197.54M
Liquidity
Debt to equity
0.13
Current ratio
2.79
Quick ratio
3.14
Net debt/EBITDA
0.25
Margins
EBITDA margin
-34,851.9%
Gross margin
-804.5%
Net margin
-37,345.4%
Operating margin
-38,735%
Efficiency
Return on assets
-55.3%
Return on equity
-70.9%
Return on invested capital
-161.8%
Return on capital employed
-66.8%
Return on sales
-37,638%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IOVA stock price

How has the Iovance Biotherapeutics stock price performed over time
Intraday
5.53%
1 week
6.47%
1 month
108.31%
1 year
130%
YTD
106.52%
QTD
106.52%

Financial performance

How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$1.19M
Gross profit
-$9.57M
Operating income
-$460.56M
Net income
-$444.04M
Gross margin
-804.5%
Net margin
-37,345.4%
The gross profit has plunged by 68% from the previous quarter
IOVA's revenue has soared by 68% QoQ
Iovance Biotherapeutics's net margin has increased by 39% from the previous quarter
The operating margin is up by 39% from the previous quarter

Growth

What is Iovance Biotherapeutics's growth rate over time

Valuation

What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
7.35
P/S
3,320.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,855.43
The EPS has grown by 24% YoY and by 9% from the previous quarter
IOVA's price to book (P/B) is 194% more than its last 4 quarters average of 2.5 and 31% more than its 5-year quarterly average of 5.6
IOVA's equity is up by 17% year-on-year but it is down by 13% since the previous quarter
IOVA's revenue has soared by 68% QoQ

Efficiency

How efficient is Iovance Biotherapeutics business performance
Iovance Biotherapeutics's ROIC has plunged by 100% YoY and by 11% from the previous quarter
The ROS has grown by 39% from the previous quarter
The ROE is up by 14% year-on-year
The return on assets has increased by 12% year-on-year

Dividends

What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IOVA.

Financial health

How did Iovance Biotherapeutics financials performed over time
The current ratio has decreased by 47% YoY and by 34% from the previous quarter
The company's quick ratio fell by 40% YoY and by 33% QoQ
Iovance Biotherapeutics's debt is 87% less than its equity
IOVA's debt to equity is down by 24% YoY but it is up by 8% from the previous quarter
IOVA's equity is up by 17% year-on-year but it is down by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.